Low-carb diet may help type 1 diabetes patients keep making some insulin

NCT ID NCT05536232

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether a low-carbohydrate diet (under 75 grams per day) can help adults with type 1 diabetes preserve their remaining insulin production. The idea is that the diet might calm the immune attack on insulin-making cells. Participants will follow the diet for a period while researchers measure insulin levels, blood sugar control, and immune markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low carbohydrate diet (under 75 g per day)
What this could lead to
If it works, this could point toward a way to preserve some natural insulin production in type 1 diabetes, potentially reducing the amount of insulin needed.
What could go wrong
This is a small, early study with only 30 participants. The diet carries a risk of ketoacidosis, and it is not yet known whether any immune benefits will be seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Oct 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old or older * type 1 diabetes for less than 20 years * willing to start a low carbohydrate diet of less than 75 g per day * under continuous glucose monitoring * having been informed about the study and having given their written and informed consent Exclusion Criteria: * already on a low carbohydrate diet of less than 100 g per day * history of ketoacidosis within the last 5 years, except during diabetes diagnosis * autoimmune disease, except thyroiditis * immunosuppressive treatment * hepatitis B virus, hepatitis C virus or human immunodeficiency virus infection * ongoing cancer or history of cancer within the past 5 years, except in situ cervical cancer or basal cell cancer with early treatment * participation to another interventional study within the past 3 months * pregnancy or breast feeding * no affiliation to a social security scheme * patients subject to legal protection measures * unability to give consent for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE1 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AP-HP - Pitié-Salpêtrière Hospital

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.